COLL - Earnings call transcript Q3 2018 | Collegium Pharmaceutical, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, ladies and gentlemen, and welcome to Collegium Pharmaceuticals Third Quarter 2018 Earnings Conference Call. At this time, all lines are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. [Operator Instructions] And as a reminder, this call is being recorded for replay purposes. I would now like to turn the conference over to Alex Dasalla, Head of Investor Relations. ahead. go Please

Alex Dasalla

Ciaffoni, to our conference Welcome Investor Pharmaceutical’s quarter Officer; by third for Brannelly, Officer; Thanks, Chief Commercial our This the Officer. is earnings Financial Joe today joined call. I Scott of Chief Alex XXXX Executive Collegium. Paul Dreyer, James. and am Collegium our Chief Dasalla, Relations Head

Litigation to Before Reform the made today statements that any we begin forward-looking of XXXX. today’s of provision call, made Act we the pursuant want Private Harbor Securities to remind participants Safe are

or that are and that litigation able and filed future and You Securities may or risks of statements product uncertainties, ER current including, such Commission. products franchise, and the may litigation be infringement cautioned forward-looking the that we involve pertaining reports will and with to in not the These Xtampza detailed our Nucynta Company’s in risks risks successfully other other incur candidates. patent periodic commercialize company without significant limitation, the prevail and risks Exchange the to not and we expense and are

this release call include certain non-GAAP discussion and information. earnings Our of will

You on our collegiumpharma.com. our non-GAAP relevant reconciliations, can website at earnings find corporate release, including

materially will differ over may current results today. our I future Our Collegium’s CEO, discussed now expectations call the Ciaffoni. turn from to Joe

Joe Ciaffoni

viewed Good the accretive profitability. the became Collegium opioid Nucynta market by Xtampza share. Collegium. ER Nucynta pain to and prescription Collegium’s is the broadened our portfolio consisting Xtampza prescribed and Collegium distinctly time all Alex. specialists. everyone, U.S. for favorably branded and to be franchise for year opioid terms joining two increased The rights thank commercialization Nucynta accelerating year-to-date to in ER is you, stakeholders afternoon. differentiated Thank is you, and XXXX, the positioned, total branded relevance of IR ER, in has to portfolio, the And transformative us. Acquiring XXXX of a continues number ER ER fastest-growing

pain with continuum options to care. Importantly, provides that people of the stay it treatment in

opioid XXXX, XX.X% portfolio of ER has market. the branded the As a September Collegium share of

necessary expertise it our building to that and are of Board support Directors. We’re organizational as our plan the progress we making with strategic and working to pertains capabilities on aspiration the leadership meaningful

increase driven towards made was Nucynta we pain million. lot versus In by Cash the acceleration $XXX.X becoming XXXX. the and to responsible a third XXX% Growth management, work Collegium in Xtampza strides quarter, on was the which leader but to the addition to of the have of have $XX.X represents the in third a net increased ER portfolio XXXX. revenue We million, of quarter franchise hand do.

secured the in ER XX bring of we’ve to that wins approximately Xtampza state are XXXX. Effective for commercial ER We and that wins represent total are at actions am wins same lives. oxycodone we at focused level. plans pleased January finishing I that these XX. ensure the additional wins ER XX million These of formulary The number our majority to on at time the announce start taking fast necessary while XXXX, strong in XXXX, X, oxycodone to exclusive

remainder commercial As growth continued we followed the a the from growth XXXX, three rate was at first to in moderated to XXXX by months the plans case throughout accelerated of see the four expect months the year. in of

implement where in oxycodone we wins first have their anticipate the controls. In exclusive in ER quarter the Part strong addition, as D we Medicare growth plans

difference molecule, from is people in of the a Assertio belief franchise, unique that lives a it a Collegium and the tapentadol relates ER the have partnership Nucynta to to and IR established make Nucynta the suffering that on anchored have pain. As strong potential shared and positive

IR either with Assertio have Maria in was announced, adversely not impacted, foundation is amend to $XXX announce company by caused to we we The agreed continued agreement XXXX. Nucynta by at impacted was for position the the for the and include the responsible the in to time a annual disruption partnership by agreement pleased are Highlights fall in contemplated was the previously commercialization supply the marketplace. depth that As guaranteed done, disruption of as longer the the ensuing new length of Nucynta supply ER too, was the lay yield, million to The deal but the obligation cash no of increases the success. certainty guaranteed Collegium reduce result a is Hurricane obligation. of transaction. been now royalty we during tiers of market partnership confusion the of will royalty sheet for levels Collegium balance the to Assertio. elimination approve of versus reaffirms for the the Collegium. the and at restructured flow details XXXX simplify Paul annual while current impact agreement value tax Collegium’s is efficiency expected accounting franchise provide Assertio. with liabilities current and minimum This our providing update. new to and transformative The that still the royalty provides sales the as fortifies the Nucynta on all has commitment to of agreement, his minimum additional to year compared our meaningful the

are We committed that we’ve proud and the to strong made, a finish. progress of we’re

We on to bolus fuel effect that the wins Xtampza the be Looking believe ahead to take acceleration oxycodone in exclusive that grow stabilize revenue able ER. XXXX, of X, prescriptions we XXXX. of January we’ll will ER believe Nucynta XXXX, payer and

to I achieve over in we’re the development to the of our pain taking Paul. mission people innovative through responsible leader suffering and now commercialization of and actions communities. call our differentiated will the products for being and necessary hand the management from pain Importantly,

Paul Brannelly

afternoon, Good everyone. Joe. Thanks,

Nucynta guaranteed million spend the is a and with structure. change moment obligation quarterly commercialization agreement most discussing The the tiered of to royalty a significant describing to Assertio. amendment like royalty $XXX switching removal I’d minimum to the of results, Before the annual

terms all amended cash net flows from revenue deal the Collegium’s net the Importantly, numbers. increase with

deal. million exchange these structure. benefits, of significant $XXX substantially We asset our eliminated the through the terminate the we our balance deal the acquisition and more initial rights efficient a improve reducing from obligation expect for In to original to benefit four-year by tax term sheet

This $X royalties for with supply million, $XXX recognizing incentives builds sales additional by issued net the at disruption. termination to a sales current revised Assertio four-year the Nucynta exercise rights, a X,XXX,XXX to Collegium’s above The and we to purchase approximately in addition to common by our XX% stock million year providing franchise warrant is price. an which change with strong below while include to of relationship million. $XXX on premium terms In the lower $XX.XX, net price grow our stock up amendment Assertio of impact the shares flow a net cash

us the objective our accelerating to terms continue deal, meet allow to Importantly, our time to main original revised in profitability. the

the filed was For see our additional details, SEC X-K afternoon. Form this please that with

the For and quarter year. recorded net in quarter $XX.X XXXX, million of of third million quarter of product of $XX.X the revenue third to this XXXX the million we compared in second $XX

second prescription the of product negatively doses XX.X% in increase third D $XXX wholesaler For revenue commercial X% ordering an Nucynta and portfolio million XXXX included while grew during for the Xtampza a of impacted quarter quarter, the for third This Part in adjustment prescriptions first second product our the net ER by million by: quarter, demand; and XX.X% and prior for was franchise. quarter of revenue period was the quarter $XX one, the net Medicare aligns Xtampza lowest shift coverage only the average three highest the wholesaler an combined The increased. gross-to-net and discount and three, the minor result was in quarters; prior in with finally, addition, orders X%, to adjustments. two third in change XX.X% to XXXX of while quarter dose the doses positive by for of included XXXX of for in the wholesalers in current as rebates, increase XXXX. the a gap gross-to-net of decreasing Medicare discount estimates of compared ordered two, mix a quarter but better

For the the and we in on basis, to expect portfolio the On remainder XX%. a discount the to remain for expect Nucynta Xtampza of low product XX% be we discount be to basis. gross-to-net range the XX% a around franchise to gross-to-net XXXX, closer ER

loss change from improvement loss $X.X million million a expenses, one-time including product by the GAAP $XX.X $X.X per quarter our For Non-GAAP loss of the the operating is in increase performance. for interest the deal-related selling net Company’s into the believe XXXX. million, core $X.X the supplement view year respectively. In XX-Q. a and loss investors our for Company’s quarters, to quarter in $X.XX management’s loss non-GAAP adjusted insight resulting actual to net press was method. We net that back loss order million non-GAAP we the compared million was adjusted the the Nucynta of quarter, of XXXX $X.XX our earnings in included result adjusted XXXX by compensation excluding is calculated quarter the included The which our of $XX.X a to release million, Nucynta and The and revenue XXXX million stock-based an $X.X royalties. third non-cash of in adjusting net and non-GAAP for quarter, share and of XXXX third prior statements, of adjusted third provides adding $XX.X loss as charge financial non-cash

downs. call with the after marks I a consecutive prior of our June million, $XX.X least Based at was quarter $XXX million seventh loan to we adjusting stock the on for million December $XXX from from flows XX over guidance improving expect September an Scott of year of and $XXX.X XX, our from in million of our now to As offerings draw increase Dreyer an cash update. term and turn This million. for cash current $X operating balance XX. the finish commercial will increase plans, cash,

Scott Dreyer

Xtampza the quarter, for it potential of and XXXX. third making prescriptions Highlights priorities, third for year-to-date ER Xtampza Xtampza period. versus time is included progress prescribers the Thanks, the franchise Nucynta stabilizing the fastest-growing slowing and quarter. second overall Paul. maximizing stabilized are ER ER third Xtampza product of second by quarter. quarter. on X,XXX flat XXXX focused and XX,XXX Nucynta since In commercial down of in decline improved Through grew ER of ER over the the delivered formulary of unaided our total XXX%, to the commercial quarter. total is third Xtampza Prescriptions accelerating exclusive quarter six quarter, opioid positions. The prescribers in XXX% XX%, ER the and first Xtampza during have quarter, the XX% growth in X% XXX,XXX new awareness the ER the launch. believe all ER prescriptions that of were over ER Total the up the we from Nucynta the third the Nucynta and second the ER continue to following; quarter in the our branded We Nucynta September, third from quarter XX,XXX one make prescriptions Nucynta to were from X% branded we were prescribed within we progressing There against franchise. that franchise ER number have IR.

ER’s promotion. OxyContin; to execution and versus made launched To strong in plans highest priorities, investment we’ve with Xtampza Xtampza to we’ve toward overall availability execution our overall priority we’ve broad We’ve positions; we is enable as our and While finish performance exclusive the in stronger commercial pull-through increased prescribe non-personal Improving progress following we’re not Xtampza streamlined we’ve taken commercial satisfied call our performance. frequency ER, HCPs, our who XXXX. drive ER; messaging focused increased with on actions:

Nucynta also Nucynta ER action, associated messaging and peripheral focus actions We novel these mechanism Xtampza only with that of is and enable the promotion Nucynta, franchise. the for diabetic ER quarter. us will we streamlined first grow non-personal neuropathic indicated the directed franchise For that prescribers pain Nucynta of on to the and increased in in neuropathy. investments fact fourth the tapentadol’s opioid believe We’ve stabilize to to dual

exclusive plans, lives the the of XX first market access of X, oxycodone Effective approximately primarily Xtampza. for commercial January additional XX oxycodone wins the XXXX. ER plans million will progress ER quarter positions in XXXX, three made at number we’ve securing ER oxycodone Part team Our An significant exclusive next D at secured and an were of covered the exclusive in added that position state in and be same level. XXXX, lives wave regional

have Blue their ER moving they communicated Shield position. an Cross Part Cross Within commercial of Cross Shield the Navitus Xtampza Blue ER D, oxycodone that and Blue channel, Blue of be EnvisionRx Tennessee in have communicated Shield ER Blue Blue Alabama Tennessee, into Xtampza exclusive XXXX. are publicly exclusive oxycodone of ER Within that and will

D lives Xtampza of Part lives. XX% With ER an these will wins, position in be exclusive of for and XX% commercial

D, as the Humana putting Optum growth medical believe are is the and also opportunity first D quarter. by We growth well Cigna-HealthSpring to as efforts. in be reduce in pull-through in This driven Collegium’s control the significant D place particularly will there XXXX, of plans within Part exceptions number the

XX% commercial execution growing to organization Our were Xtampza up renewal understanding for exceptions through is now quarter. Nucynta The stabilizing approved that in XXXX, for of will for which turn the first XXXX. approximately OxyContin, in I’ll is operational and be ER it medical of improved back laser-focused the on remainder the Joe. franchise

Joe Ciaffoni

Thanks, Scott.

We will questions. open it now up for

Operator

Thank you. with question first Instructions] Amsellem [Operator Our Jaffray. from David comes Piper

now is line Your open.

David Amsellem

Thanks.

Just have a few.

regions understand talk inherited whether where gain and on wins. was But those then And you regional to the have or state this you for or potential also Nucynta. access helpful. where is commercial formulary looking wondering and plans, from the negotiations? national the you the states question. need secondly, wins to And color nationally? payer Depomed question So a can then, again, I yet mean, first you now last Assertio. that it’s elaborate I The can D about for? regarding improve large I is are guess, on you and is access you access you’re just where, on Part And on And exclusivity the us specific plans, contracts Xtampza help if on

the needs major for So the there that terms expecting? any any I question XXXX, any products should changes be do that changes And back for major contractually is we regarding Thanks. going just – guess are forward? those you there be think is to there

Joe Ciaffoni

try is Joe. questions. which I’ll in this through the the forward. David, order them put walk for them to Thanks in you

with focus the regional year, formulary our with our part lives the Xtampza coverage keep strategy we payers. of commercial in So and good first of XX%. perspective, off to and overall as have state it in the availability more are have we wins, throughout feel national as to move our rates We To XX% to ER and is communicated focus. down our paid

to be space phase to final Nucynta, would it say we’ve on through we’ve pertains evolve the contracts and at Nucynta prior states. state wins to is it think payer would the I you of that focused we’re population So as do beginning the guide. the as the worked so that as into And to on, to the you that inherited. your were the question to forward will that, Nucynta, I share ones the we’re of course approval differently. is Nucynta level. some wins states, now instances focusing secured if where get or not go down think market then states, announce position fair least, we XXXX, in XXXX have are opportunity to to plans become bring your contracts to are able some exclusive we of an to what into couple year to plans will biggest the we follow movement. the are a can which say final which We not, their in through I at the some performing, any would around that add we we to prior question as think on which or of the that the the To big we’ve in year, plan things we’ve trying the And a year, phase integration people was know, carried From the in because ER oxycodone of to we with of the regards question as and we on focus certainly what announcements, now

Okay?

David Amsellem

the follow-up we addition and just the on contract, may Okay, I all the should gross-to-net that’s next just just given exclusive sneak the in up helpful. contracts? higher year, creep expect new of a to gross-to-net, If given exclusive

Paul Brannelly

Paul. is This David. Hi,

expect and we our and someone customer the low like become to we’re XX% range grow business, as wholesalers, we for So some returns. there, potential to the then things for stay significant gross-to-net have allowance we’ve think potentially because room able more a like we in

right it’ll the So – think range. we this current in stay

David Amsellem

Thanks.

Joe Ciaffoni

David. Thanks,

Operator

you. Thank

Company. Serge Belanger question from with Needham next comes Our &

Your line is now open.

Serge Belanger

afternoon. good of Xtampza. questions A on Hi, couple

Can First the in formulary fourth levels of additional the expect one for any the inventory you of And these quarter ahead wins? just whether on comment Paul. you quarter? major changes Xtampza third XX over

Paul Brannelly

question. Hi, Serge, thanks for the

coming So doses levels much we for third pretty were we see ordering. that remarks stayed inventory see in quarter, did they said down the the I the what same. wholesalers the prepared the that did What and on is

shift, that reacting but coming we we’ve What the last over any the we’ve there’s or stocking plans with quarters stocking. now handful that’s on quarter where exclusive expect happen actually when see destocking quarter. coming And So we the seen with new demand, seen and actual major in is pharmacies the third in don’t contracts in of board. fourth –

see that’s in more So something, I the quarter than ahead so we’d fourth think, those. the of quarter first in

Serge Belanger

Okay. then on far Joe kind you seen expectations? of year. so commented to you in on your growth the elaborate the that? you Xtampza in for met we’ve on the XXXX, you second progression terms wanted the comment or of in of that just prescription what can Scott, And if And just half expect Has

Joe Ciaffoni

So, then maybe some XXXX on back with XXXX. Scott hand the to Serge, portion I’ll come commentary and over

Scott Dreyer

question, thanks Yes, for Serge. the

that momentum XXXX. the in is knew Joe? that execution, our in the we So focused third in in satisfied. so wins on come quarter, on of the access the focused on bolus would the had in increasing But market before of pull-through growth fourth further moderate. we extending focus quarter build that, do prescription terms on to we’re And of nonpersonal the and quarter. not today, can we’re of first half our and fourth said, growth as exponential we’re the our in growth I’ve We year the

Joe Ciaffoni

Serge, think we commercial which there’s occurs, experience to specific is the not And We fundamental disruption enough the reiterate, that now with to with happens plans those ER that plans. what that to I’ll we of conversion typical. as is have the be and know XXXX, the thing ER marketplace

of we when would accelerated to half we the year, think the So of expect growth first year. be the in

the in commercial believe we’re gets would have growing quarter, candidly, to and half. and what fourth and both us be But the to I quicker quarter would it in expect I moderate think the seeing execution. third to – which second

focus, and particular, in get where see think so on perspective, be care this a to that our than focus message when our is And us second we the perform delivery we we year. from managed continue we plans have that have position I improving benefit I contracted of what year performed where better the the – should expect would pull-through, execution the in next get to nonexclusive, to we’ve half a

Serge Belanger

Okay.

Let me sneak Nucynta. last in one one for

should Now – expect product we modified that ER make you the the to the stabilize in additional agreement, this franchise to you royalty investments and grow invest products?

Joe Ciaffoni

Yes.

we’ll I level So have you that the in in we is invest good at question, Serge, a to should XXXX. continue it is where that think product what expect

we’re year, of it this in that the $X Collegium flow. the were year, – But a think sales Nucynta in what’s as of come million a about presence, was franchise. in publication, additional structure for that have around cost would context terms next mean overall I we have. the I place plan think basis the have moves if structure terms in Nucynta be from year, it the effect the a driving agreement, on leveraging we out organization, we’ll education cash in in strong to cost of the or we we conference In

Serge Belanger

Thank you.

Operator

Thank you.

comes Jefferies. Our from next question with Steinberg David

open. now is line Your

David Steinberg

Three Thanks. questions.

up XX just that period think of I lives. say care managed that wins booked with million, did lives million XX around you quarter. negotiation, be in range. a have, like Can started $XX Secondly, covering million million you the you the will clarify, also said the covered SG&A XX this you same XXXX? on the First, you during you’ve million to as $XX been It running you ticked January looked line, $XX

for rate that third your there of new And one-offs? run any were then So SG&A? Or just is sort strategically.

are strategic of And and There’s bought in those they’re in you drugs out of I development, was aren’t is sell said sort abuse-deterrent the that went a of non-ADF portfolio. market more their portfolio their started to Thanks. You as off you fentanyl-based And for become on recently pain marketed products potentially opioid. exploring with and something curious then companies still you to lookout many just a alternatives pain/opioid company an opioid. the pain there and this that company? – expand

Joe Ciaffoni

Sure.

So managed right? your is ask care; Joe. on on the Paul, question for to third Thanks the going David, on answer come to I’m and Scott the SG&A; question question, questions. I’ll then back this

Scott Dreyer

in if David. XX so was exclusive were to a I Thanks, XXXX the from amount at going moving to to XXXX, same from speaking from lives Yes, position million is is an what XXXX of XXXX amount essentially you the look added Paul? the that standpoint. life

Paul Brannelly

well David third And rate consulting additional as as some your question litigation about large the litigation, on current what is, expenses – run some Great. quarter expenses. one-time the SG&A one-time included

litigation will over years, the a Of course, the in was what little piece next we’ve it bit of than more seen so quarter third but lumpy historically. couple the be

Joe Ciaffoni

then, is And this Joe. David,

There the currently understand much is work the coming exercise as have trajectory the five-year how stream: are and with are the the the portfolio feel do company with we’re capabilities and for really will pain to strategic the on question, third to financial up focused through where we a board. strategy components deep competitive landscape. the stream generate; work cash is out what entire the the and current digging second On work one the you stream organization’s mapping is is three we working advantage; know, what first

was molecule. acquired is formulation, we franchise, feel abuse-deterrent we started the differentiated an which Nucynta Collegium with Although a

would not management. we part And that you’re our growth interested a opportunity regards is of one be that in say why the of talking to responsible pain I would next solutions, nonopioid want which in. are to also of with that about, inclusive that wave We mission, on we be focus

David Steinberg

Thanks color. for Great. the

Operator

you. Thank

with Blair. Lugo Our comes Tim question from next William

Your line open. is now

Myles Minter

for question. Hi, Myles for William Thanks the Minter, Lugo, Blair. on Tim taking

got couple. a just So

ramping recent the that’s to going act, Given you a do be decline, think forward? And Or script there formulation relief And trends Nucynta a to passing moving after instant that? with it SUPPORT of between offset portion? going the you something that. ER real-time is the impact a XX% going to forward? like can got moving actually how Thanks. be is that Nucynta follow-up I’ve in discrepancy those the And

Paul Brannelly

Paul. Hi, this Great. Myles, is

market. As putting policies come to recent market, think go, days, we litigation, around there. should within prescriptions, the before, entire far IR far pharmacies IR IR have But than lot as pressure but of state on some size decline out still it’s and five, and rate but own as That that will overall as a of lot slower as the a of with it outperform Nucynta the we’ve whether IR their market. is even products three, limits different a the it’s centered at whether seven IR continue rules overall have said prescriptions different

Myles Minter

of on helpful. formulations not that’s do ramping – And extended-release you the or Okay, any on assumptions commenting have that? you

Joe Ciaffoni

So Myles, this is Joe.

a don’t we slowing decline coupled, year-on-year. And I’ve guidance. now said we the ER. the position we’re believe us would stabilized we’ll know, rate that what the revenue the a we’ve script, with reiterate confident believe say in of progress. grow What where will the do ER in in of We the you As would give put IR, and I

Myles Minter

exclusive are in Xtampza for how clarification a the just many quarter lives And XXXX? actually question, and

Scott Dreyer

right lives I commercial, part D lives exclusive understood So XX% you, and to move year, – about Myles, if of still be we’re XX% I And at D exclusive XX% XXXX, lives. lives. in of look think and XX% we Part of at at XX%, we’ll next you as XX% now, versus exclusive in about XXXX if of commercial our lives

Myles Minter

Great, the Thanks for beautiful. questions.

Scott Dreyer

Myles. you, Thank

Operator

Thank you.

question with comes next Folkes Cantor from Our Brandon Fitzgerald.

now Your line is open.

Brandon Folkes

question. my taking for thanks Hi,

sales time ER? the XXXX Just how to investing moving do opposed balance Xtampza do reps terms in is versus beyond. one particular you and when to you. you Xtampza thing picture it prescribe into seems Thank is around the as Nucynta Nucynta? of And in balance on what behind How the differentiation specialists

Joe Ciaffoni

second So rate. leverage, of Brandon, to question, first that Scott. corporate I’ll leverage the get the priority we of and And just reinforce of operational organization. When grow number is the into broadly when everything is to you to XXXX, priority take that, our want the perspective, one our add priority cost structure ER our hand is of to that your look continue we to. we And one on from first to in Xtampza We will structure believe supportive look accelerated how or potential growth calls that not terms is part and maximize our to I the of do Nucynta operationally, the add Xtampza franchise. would we we incentive position, other parts through a

Scott Dreyer

at when at novel fact able to, add unique a the we the and a versus Xtampza products the different MOA physicians, and molecule patients the I promote The effectively would what a to focus of the overlapping meet needs of call is on can that that call in OxyContin, differentiation the because continuum. Nucynta both said point look engagement Joe of only with of we’re with thing is the a points,

able be a so in And and that’s balance we’re how a call. of given to efficient put promotion

Joe Ciaffoni

business one I is there Brandon, Xtampza sources to difference relative a of Nucynta would thing ER. other how add, And

tramadol of that with a XX% neuropathic mix the it sources XX% XX% the component. than IR So have its as is portion less business sources of to ER its from Xtampza from for often and you diabetic it pain sources and to sources of ER With focus indication, more is thought conversion. Nucynta ER, And market IR know, Xtampza of, oxycodone IR, differently, by hydrocodone Nucynta ER is peripheral and oxycodone. from our patients oxycodone. the market XX% neuropathy business it driven this of from because

So differentiated, pain that’s specialists. research with distinctly where and and do feel our we in back positioned we that played they’re that’s to us

Brandon Folkes

Thank helpful. you. That’s very

Operator

with Our from [Operator Instructions] Kevin question comes next Kedra you. Gabelli. Thank

is now Your open. line

Kevin Kedra

Thanks for taking the questions.

the wins to you expect First, XXXX. to go back I want for

covered force. think those the similar at You expect in similar fair Would of moderate? you that it have of looking efforts, the to to considered sales sales the a thoughts be what wins QX XXXX? your size given secondly, of to XXXX. around different of be at around at into in selling saw we’ve ask to I are prescriptions said kind once want maximize number performance new seems that to of the beginning you especially increase contract guys force, seen that couple you looking going But of magnitude will kind the lives know And of then, about I of the Nucynta. ways that boost you from

Joe Ciaffoni

So the to hand the Kevin, question force first question I’ll take sales and Scott.

the number of be As a opportunity. would think think we overall to it’s payer you of think lives, reasonable I similar it if say of opportunities, equal

impact positions those we be those we’ve the we come in Medicare that we’re the exceptions first about is business, XX% OxyContin. those patients, due for approved in commercial quarter. who I would believe in things of of Part on new to second the D occur exclusive first ER So where have excited as medical about we’ll the think of had the And also oxycodone the quarter. books again are important within opportunity emphasize wins one particular the is

Scott Dreyer

our look coverage we looking at sales as our When base. of always our and Kevin. planning annual Thanks, force, footprint at we’re our process, customer our of part

XX% cover when now, of ER and we the on put the stability. we representatives market. a have you almost Nucynta IR ER, opportunity, Xtampza of Right that so targets, XX,XXX XX% branded XX% the Nucynta look and of at premium XX% of XXX we And operational the big

where And coverage we and on there. the feel maximizing real matter we so relationships of deployed, that that about have we’re are and focused the good the fact is,

Operator

further Thank in questions no showing you. I am queue.

to over So turn I’d for like Alex to it closing remarks. Dasalla back

Alex Dasalla

hand I’ll it Joe over to close. to

Joe Ciaffoni

Once for be joining again, for thank this year transformative afternoon. Collegium. to a you XXXX us continues

ensure in to and and everyday to We’re that note, a Collegium effort positive of to to XXXX. for recognize the we communities. their I taking from encouraged the thank they necessary by final off strong. my want people in making finishing for lives commitment actions forth the On pain we’re suffering to At same great that time, a a fast a at on our and evening. difference our the accomplishments, a take Have laser-focused moment in get put start colleagues

Operator

does a and our you. day. have ladies And great Please, for conclude that today. Thank conference gentlemen,

You a day. Have may now wonderful disconnect.

Collegium Pharmaceutical (COLL) 8 Nov 182018 Q3 Earnings call transcript